Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 3.02B +8.6% |
| Revenue (ttm) | 588.99M +19.8% |
| Net Income | 214.33M +30.8% |
| EPS | 1.68 +28.2% |
| Shares Out | 122.12M |
| PE Ratio | 14.70 |
| Forward PE | 13.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,025,973 |
| Open | 24.21 |
| Previous Close | 23.92 |
| Day's Range | 23.73 - 24.80 |
| 52-Week Range | 19.05 - 26.58 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 35.00 (+41.76%) |
| Earnings Date | Feb 25, 2026 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticoste... [Read more]
Financial Performance
In 2025, Catalyst Pharmaceuticals's revenue was $588.99 million, an increase of 19.78% compared to the previous year's $491.73 million. Earnings were $214.33 million, an increase of 30.78%.
Financial StatementsAnalyst Summary
According to one analyst, the rating for CPRX stock is "Strong Buy" and the 12-month stock price target is $35.0.
News
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FI...
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs
Catalyst Pharmaceuticals management asserts a $1B+ LEMS market opportunity, estimating 3,600–5,400 addressable patients, with growth driven by improved diagnosis and market penetration. Recent present...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution
Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. ( CPRX) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Michael Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Direct...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guida...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and c...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in Fe...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in Fe...
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Jeffrey Del Carmen - Executive VP & Chief Commercial Officer Michael W. Ka...
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% Yo Y, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an ...